Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Ablynx Loses Pfizer, Gains Merck Serono
by Rick Mullin
November 14, 2011
| A version of this story appeared in
Volume 89, Issue 46
Ablynx, a Belgian biopharmaceutical company, has regained worldwide rights from Pfizer to develop its Nanobody antibody fragments targeting TNF-α. They include rights to ATN-103, a rheumatoid arthritis treatment that successfully completed Phase II clinical trials in May. Ablynx launched the project in 2009 with Wyeth, which Pfizer acquired. Pfizer says it returned the program as part of a portfolio review. Meanwhile, Ablynx has launched its third Nanobody partnership with Merck Serono. Ablynx will receive an up-front payment of $27 million for the new project plus $20 million for each Nanobody that advances to clinical trials.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter